GlaxoSmithKline
π¬π§United Kingdom
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general med...
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 240
- Registration Number
- NCT06431594
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 100
- Registration Number
- NCT06422767
- Locations
- πΊπΈ
GSK Investigational Site, Austin, Texas, United States
A Study to Investigate the Safety and Pharmacological Effect of a Single Intravenous Infusion of Belantamab in Male and Female Participants Aged 18 to 75 With Moderate to Severe Systemic Lupus Erythematosus
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 16
- Registration Number
- NCT06413511
- Locations
- πΊπΈ
GSK Investigational Site, Peachtree Corners, Georgia, United States
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
- First Posted Date
- 2024-05-13
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 350
- Registration Number
- NCT06411249
- Locations
- πͺπΈ
GSK Investigational Site, Vilajoyosa, Spain
Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Patient-derived Organoids and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 40
- Registration Number
- NCT06405230
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1457
- Registration Number
- NCT06389487
- Locations
- πΏπ¦
GSK Investigational Site, Reiger Park, South Africa
A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults
Phase 1
Recruiting
- Conditions
- Interventions
- Biological: Flu Pandemic mRNA_Dose level 2Biological: Flu Pandemic mRNA_ Dose level 3.Drug: PlaceboBiological: Flu Pandemic mRNA_Dose level 5Biological: Flu Pandemic mRNA_ Dose level 4Biological: Flu Pandemic mRNA_Dose level 1Biological: Flu Pandemic mRNA_Dose level 6Biological: Flu Pandemic mRNA_Dose level 7
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1080
- Registration Number
- NCT06382311
- Locations
- πΊπΈ
GSK Investigational Site, Seattle, Washington, United States
Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma
Phase 4
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1136
- Registration Number
- NCT06372496
- Locations
- π¨π³
GSK Investigational Site, Taichung, Taiwan
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 842
- Registration Number
- NCT06374394
- Locations
- πͺπΈ
GSK Investigational Site, Madrid, Spain
A Study to Investigate the Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With GSK3036656 in Female Participants of Non-childbearing Potential Aged 18 to 65 Years of Age
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 25
- Registration Number
- NCT06354257
- Locations
- πͺπΈ
GSK Investigational Site, Madrid, Spain
Β© Copyright 2024. All Rights Reserved by MedPath